TABLE 1

Overview of the Demographic Data and Results

Patient no.*Age (y)SexEtiologyStageAdministered activity (GBq)Dicentrics/cell
PrePost1Post2
IL151FHCVChild A/B1.930.0000.073
IL2a63MEthanolChild A1.900.0200.0650.130
IL2b63MEthanolChild A2.090.0030.0870.130
IL3a64MHCV + HBCChild A1.770.0000.0200.060
IL3b64MHCV + HBCChild A1.730.0130.0370.073
IL4a54MHeCh + ethanolChild A1.920.0070.0830.140
IL4b54MHeCh + ethanolChild A1.640.0820.1830.233
IL4c54MHeCh + ethanolChild A1.950.1570.2700.357
IL557MEthanolChild A2.020.0000.050
IL671MHCV + ethanolChild B2.020.0100.267
IL760MHBVChild B1.970.0000.020
IL855MHCVChild A2.050.0100.093
IL964FHCVChild A2.050.0000.0600.083
IL1061MHCVChild A1.790.0000.1230.127
IL1172FHCVChild A1.880.0000.2300.247
IL1253FHCVChild B1.950.0030.027
IL1324FFibrolamellar1.840.0070.0300.045
IL1459FHCVChild A1.450.0070.062
IL1563MHCVChild A1.880.0000.2670.267
IL1687MEthanolChild A1.990.0030.1430.157
Mean1.890.0160.1010.165
SD0.160.0380.0810.094
ReL1a71FHCVChild A3.730.1910.2570.310
ReL1b71FHCVChild A3.720.2670.3350.302
ReL1c71FHCVChild A3.270.2430.3040.373
ReL270MHCV + ethanolChild B3.480.0670.1220.159
ReL370MEthanolChild B3.410.0000.0200.043
ReL468MHCVChild B3.740.0130.0500.060
ReL560FHCVChild A3.580.0000.1000.150
ReL6a71MHCVChild A3.710.0000.1230.120
ReL6b72MHCVChild A3.660.1000.1800.194
ReL7a75MHeChChild A3.540.0000.0370.050
ReL7b75MHeChChild A3.350.0800.1430.157
Mean3.560.0870.1520.174
SD0.170.1020.1070.111
  • * The final letter (a–c) indicates different therapies for the same patient.

  • At time of treatment.

  • Pre = before administration of the radionuclide; Post1 = 7 d (131I-lipiodol) or 1 d (188Re-HDD/lipiodol) after administration of the radionuclide; Post2 = 14 d (131I-lipiodol) or 2 d (188Re-HDD/lipiodol) after administration of the radionuclide; HCV = hepatitis C virus; HBV = hepatitis B virus; HeCh = hemochromatosis.